15d-PGJ2:: The anti-inflammatory prostaglandin?

被引:276
作者
Scher, JU
Pillinger, MH
机构
[1] NYU, Sch Med, Div Rheumatol, New York, NY 10003 USA
[2] Hosp Joint Dis & Med Ctr, New York, NY 10003 USA
[3] Manhattan VA Hosp, NY Harbor Healthcare Syst, New York, NY 10010 USA
关键词
prostaglandin; 15d-PGJ(2); PPAR-gamma; inflammation; PGD(2); H-PGDS; L-PGDS; NF-kappa B; Er; k;
D O I
10.1016/j.clim.2004.09.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
15-Deoxy-Delta-(12,14)-prostaglandin J(2) (15d-PGJ(2)) is the most recently discovered prostaglandin. This cyclopentatione, the dehydration end product of PGD(2), differs from other prostaglandins in several respects. There is no specific prostaglandin synthase (PGS) leading to 15d-PGJ(2) production and no specific 15d-PGJ2 receptor has been identified to date. Instead, 15d-PGJ2 has been shown to act via PGD2 receptors (DP1 and DP2) and through interaction with intracellular targets. In particular, 15d-PGJ2 is recognized as the endogenous ligand for the intranuclear receptor PPARgamma. This property is responsible for many of the 15d-PGJ(2) anti-inflammatory functions. In this review, we summarize the current understanding of 15d-PGJ2 synthesis, biology and main effects both in molecular physiology and pathological states. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:100 / 109
页数:10
相关论文
共 144 条
  • [1] Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
    Adams, M
    Montague, CT
    Prins, JB
    Holder, JC
    Smith, SA
    Sanders, L
    Digby, JE
    Sewter, CP
    Lazar, MA
    Chatterjee, VKK
    O'Rahilly, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) : 3149 - 3153
  • [2] PPAR gamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
    Altiok, S
    Xu, M
    Spiegelman, BM
    [J]. GENES & DEVELOPMENT, 1997, 11 (15) : 1987 - 1998
  • [3] Arimura A, 2001, J PHARMACOL EXP THER, V298, P411
  • [4] Attur M, 2003, ARTHRITIS RHEUM, V48, pS430
  • [5] 15-Deoxy-Δ12,14-prostaglandin J2 inhibits IL-10 and IL-12 production by macrophages
    Azuma, Y
    Shinohara, R
    Wang, PL
    Ohura, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (02) : 344 - 346
  • [6] Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the litigation of PPARγ
    Bell-Parikh, LC
    Ide, T
    Lawson, JA
    McNamara, P
    Reilly, M
    FitzGerald, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (06) : 945 - 955
  • [7] Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2
    Bishop-Bailey, D
    Hla, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) : 17042 - 17048
  • [8] Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage -: PPARγ activation modulates the effects of interleukin-1β on rat chondrocytes
    Bordji, K
    Grillasca, JP
    Gouze, JN
    Magdalou, J
    Schohn, H
    Keller, JM
    Bianchi, A
    Dauça, M
    Netter, P
    Terlain, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) : 12243 - 12250
  • [9] Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
    Braissant, O
    Foufelle, F
    Scotto, C
    Dauca, M
    Wahli, W
    [J]. ENDOCRINOLOGY, 1996, 137 (01) : 354 - 366
  • [10] Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
    Burstein, HJ
    Demetri, GD
    Mueller, E
    Sarraf, P
    Spiegelman, BM
    Winer, EP
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) : 391 - 397